More Americans are turning to AI to solve problems in their everyday lives. Recent studies show that healthcare is no exception. For the underinsured, the rural, the disabled, and anyone too stigmatized to ask a pharmacist about the drugs they are actually taking, AI chatbots are becoming an increasingly attractive source of drug information.
The crystallizing liability landscape, anchored by Garcia v. Character Technologies’ treatment of AI outputs as products, creates perverse incentives toward either surveillance-heavy monitoring or blanket refusal to engage with drug queries. This Essay proposes an alternate path grounded in harm reduction principles already embedded in pharmacist duty doctrine developed over four decades in state courts. These existing duties, mapped onto AI systems through targeted refusals, accurate pharmacological information, nonjudgmental risk warnings, data minimization, and crisis pathways, provide an actionable liability framework before more deaths force reactive regulatory responses.